Simple Summary The reactivation of embryonic developmental programs is crucial for melanoma cells to grow and to metastasize. are first induced to differentiate into neural crest cells, then into melanoblasts and finally are matured into melanin producing melanocytes which correctly home to the basement membrane in an organotypic skin reconstruction assay [50,51]. The induction of neural crest cells at the neural plate border before undergoing EMT and migrating out of the neural tube relies on BMP, WNT, Notch/Delta and FGF signaling coming from the surrounding embryonic tissues [52]. Phenotypic differentiation into peripheral neurons, glia cells, bone and cartilage of the head, smooth muscle cells, melanocytes and endocrine cells will be strongly modulated by the neural crest cells spatial identity along the neural tube and onset of migration [53]. According to these developmental programs there are several ways of differentiating neural crest cells from hPSCs and high Bisoctrizole tumorigenic potential, while the others are the melanocytes themselves, a more differentiated cell population with only low potential of renewal. In general, melanoma initiating stem cells are positive for stem cell markers, such as Compact disc133 and Compact disc271 and show morphological, phenotypic and practical top features of a stem cell human population. Cells positive for these markers can handle generating supplementary tumors in nude mice [107]. The microenvironment of melanoma-initiating cells consists of, besides keratinocytes, fibroblasts also, endothelial cells and disease fighting capability cells, which give a wealthy repertoire of secreted substances which help in cell motility, invasion and angiogenesis [80]. The tumor cells themselves secrete soluble elements to get ready their homing site actually before it really is reached by them, such as for example VEGF, GCSF, FGF2, TGF- and PDGF [146]. These elements, among others, alter the ECM Rabbit Polyclonal to HTR5A and recruit myeloid cells with immune-suppressive properties, so-called myelo-derived suppressive cells, tumor-associated macrophages or tolerogenic dendritic cells. The formation is enabled by This technique of metastases and protects tumor cells through the disease fighting capability [147]. Defense privileged sites, like the optical attention and the mind, appear to be desired colonization sites by melanoma cells. Metastatic pass on is considered to become probably the most inefficient step in melanoma progression [148]. Still metastasis is the major reason why patients succumb to this often fatal disease. Inhibition of the metastatic process is the major aim for the future and insights into developmental cues may hold the key for novel and effective therapeutic approaches. 7. Conclusion and Possible Therapeutic Options for Future Melanoma Treatment Here, we reviewed, on the one hand, the developmental process of neural crest induction and, on the other hand, discussed factors which contribute to melanocytic differentiation. We have summarized molecular clues instrumental for establishing neural crest and melanocyte progenitor cells. A number of molecular markers are available Bisoctrizole to identify these cell populations as already outlined in Table 1. The transition from the progenitor pool to differentiated melanocytes is accompanied by up-regulation of the MITF pathway, which controls pigmentation, but also other melanocyte specific characteristics. The knowledge gathered from developmental programs occurring during embryonic skin development can be used in order to gain mechanistic insights into the process of malignant melanoma formation and progression. Especially, the metastatic process in melanoma can be associated with a switch in developmental states. On the one hand, melanoma cells in the migrative and invasive phase express prominent neural crest cell marker profiles, including genes controlling stemness. Bisoctrizole On the other hand, cells which stopped migrating and adopted a proliferative phenotype express differentiation associated genes. A model for the dynamic process of phenotype switching is shown in Figure 2. Open in a separate window Figure 2 Dynamic process of phenotype switching in human melanoma..